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Abstract 
Purpose: The pH discrepancy between healthy and atopic dermatitis skin was identified as a 
site specific trigger for delivering hydrocortisone from microcapsules.  
Methods: Using Eudragit L100, a pH-responsive polymer which dissolves at pH 6, 
hydrocortisone-loaded microparticles were produced by oil-in-oil microencapsulation or 
spray drying. Release and permeation of hydrocortisone from microparticles alone or in gels 
was assessed and preliminary stability data was determined. 
Results: Drug release from microparticles was pH-dependent though the particles produced 
by spray drying also gave significant non-pH dependent burst release, resulting from their 
porous nature or from drug enrichment on the surface of these particles. This pH-responsive 
release was maintained upon incorporation of the oil-in-oil microparticles into Carbopol- and 
HPMC-based gel formulations. In-vitro studies showed 4 to 5-fold higher drug permeation 
through porcine skin from the gels at pH 7 compared to pH 5.  
Conclusions: Permeation studies showed that the oil-in-oil generated particles deliver 
essentially no drug at normal (intact) skin pH (5.0 – 5.5) but that delivery can be triggered 
and targeted to atopic dermatitis skin where the pH is elevated. The incorporation of these 
microparticles into Carbopol- and HPMC-based aqueous gel formulations demonstrated good 
stability and pH-responsive permeation into porcine skin. 
Keywords 
pH-responsive microparticles, Eudragit L100, hydrocortisone, Carbopol, hydroxypropyl 
methyl cellulose. 
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1 Introduction 
The introduction of anti-inflammatory topical steroids into medicine about 50 years ago 
represents a significant landmark in dermatologic therapy and remains to date the mainstay of 
atopic dermatitis management (1). Although hydrocortisone is regarded as a safe alternative 
to the more potent corticosteroids, its “over-the-counter” availability makes it particularly 
liable for abuse. The use of more potent steroids, especially when treating paediatric patients, 
can cause serious systemic side effects such as hypothalamic-pituitary-adrenal axis 
suppression and it has been reported that as little as 2 g per day of clobetasol propionate, 
0.05% w/w cream, can decrease morning cortisol levels after only a few days (2). 
There is a clear need to optimise these therapies using drug delivery strategies. Ideally, new 
glucocorticoids with a better therapeutic index need to be developed. However, this is 
difficult to achieve as the receptors responsible for drug activity are also responsible for the 
occurrence of side effects. Novel selective glucocorticoid receptor ligands with better 
therapeutic profiles are being developed (3), but site-specific delivery strategies, such as drug 
encapsulation, offers an alternative approach for minimising adverse reactions.   
The pH discrepancy between normal and atopic dermatitis skin provides a potential trigger 
for a controlled release formulation. Normal pH on the surface of adult skin is in the range of 
5.0 to 5.9, depending on age, gender and body area (4-6). However, in the case of atopic 
dermatitis, there is a trend of increased stratum corneum surface alkalinity with reported pH 
values approximately 0.5 unit higher in patients with AD than in controls with healthy skin  
(pH of ~ 6 or over in diseased skin) (4, 7). A correlation between disease severity and surface 
skin pH was also observed. For instance, surface skin pH increases up to 7.3-7.4 in acute 
eczema with erosion (8). A trend towards more elevated pH values was also observed in non-
involved skin of seborrhetic dermatitis, atopic dermatitis and xeroderma patients (9).  
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This study explores the use of pH-responsive polymeric microparticulates for site-specific 
corticosteroid delivery to treat atopic dermatitis. Eudragit L100, a polymer with a dissolution 
threshold of pH 6, was used to produce hydrocortisone-loaded microparticles by spray drying 
and oil-in-oil solvent evaporation methods. Drug release from both batches of microparticles 
was first evaluated to determine the degree of their pH-responsiveness and the mechanisms of 
drug release. The microparticles with the best pH-controlled release profiles were formulated 
into several aqueous gel preparations. In-vitro hydrocortisone permeation from the 
microparticles and formulations was assessed and a preliminary stability study was 
performed to examine drug leakage from the microparticles which would result in a loss of 
pH-responsiveness. 
2 Materials and methods 
2.1 Materials 
Hydrocortisone was purchased from Sigma-Aldrich (UK). Eudragit L100 was kindly 
provided by Röhm (Germany). Ethanol, hexane (laboratory grades) and sorbitan sesquioleate 
were obtained from Sigma-Aldrich (UK). Sodium dodecyl sulfate and Liquid Paraffin BP 
were purchased from Fisher Scientific (UK). Sodium phosphate dibasic heptahydrate and 
sodium phosphate monobasic dehydrate (Sigma-Aldrich, UK) were used to prepare the 
dissolution media. Carbopol 940 (Acros Organics, Belgium) and Metolose 90SH-SR 
(hydroxypropyl methyl cellulose, HPMC) (Shin Etsu, Japan) were used for aqueous gel 
preparation. Nitrocellulose membranes (MF membrane, pore size 0.22 µm, 25 mm diameter) 
used in diffusion testing were purchased from Sigma Aldrich, UK. 
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2.2 Preparation of pH-responsive microparticles 
Hydrocortisone-loaded Eudragit L100 microparticles were produced using the spray drying 
and oil-in-oil solvent emulsification methods as detailed in our previous articles (10, 11). 
Briefly, a 2.5% w/v polymeric feed solution was spray dried from a 50:50 v/v ethanol/water 
co-solvent system using the following parameters; a 1.5 ml/min feed rate, a 28 m
3
/h flow of 
heated nitrogen and an inlet temperature of 70
o
C. To obtain the oil-in-oil microparticles, a 
10% w/v polymer ethanolic solution was emulsified in liquid paraffin and stirred overnight at 
1200 rpm to allow for complete solvent evaporation and particle solidification (12). The drug 
was incorporated into the polymeric microparticles at 2.5, 10 and 25% w/w loading with 
respect to polymer weight.  
2.3 Preparation of gel formulations 
Eudragit L100 microparticles prepared from the oil-in-oil emulsification process at 10% w/w 
drug loading were incorporated into aqueous formulations gelled with either 1.5% w/v 
Carbopol 940 or 2% w/v Metolose 90SH-SR and containing 1% w/v phenoxyethanol 
(ethyleneglycol-monophenyl ether) as a preservative. The final concentration of 
hydrocortisone within all gel preparations was 1% w/w. 
2.4 Release studies 
Release testing of hydrocortisone-loaded Eudragit L100 microparticles used nitrocellulose 
membranes in Franz-type diffusion cells with receptor compartments containing 15 ml of 0.1 
M phosphate buffer solutions with pH’s ranging from 5 to 7. A finite amount of the 
microparticles was used in the donor compartment: 0.5 mg, 3.3 mg and 12 mg for 25, 10 and 
2.5% w/w drug-loaded microparticles (C<0.1 Cs upon complete drug release), over a surface 
area of 3.14 cm
2
. The Franz-cells were immersed in a water bath at 37±1
0
 C in order to 
maintain the membrane surface temperature at 32±1
0
 C. Samples (1ml) were taken 
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periodically from the receptor compartment, replaced with fresh pre-heated phosphate buffer 
and analysed using UV spectroscopy at 248 nm.  
2.5 Permeation studies 
Although human skin is the most relevant membrane for percutaneous drug absorption, due 
to its limited availability for experimental use, a wide range of animal models has been 
investigated as a replacement. Porcine skin was found to be a good surrogate for human skin 
in a number of in-vitro studies (e.g. 13, 14) and was used in this study.  Pig ears were 
obtained from a local abattoir (within 6 hrs of animal sacrifice), cleaned under cold running 
water before full thickness skin was removed from the underlying cartilage (frozen skin was 
used within 2 month). Permeation experiments were performed using Franz-type diffusion 
cells (receptor volume 15 ml, surface area 3.14 cm
2
). Full thickness skin (mean thickness 
1.20±0.15 mm, n=20) was mounted between the donor and receptor compartments with the 
stratum corneum side up before equilibration with the receptor buffer pH for 2 hours prior to 
the experiment.  10% w/w Hydrocortisone-loaded microparticles or 1% w/w hydrocortisone 
Carbopol- and Metolose-based gel preparations were then applied to the skin at a finite dose 
(3.3 mg of microparticles and 30 mg of gel). The permeation studies were performed under 
occlusion with Parafilm to ensure hydration and equilibration of the stratum corneum with 
the phosphate buffer receptor at pH 5 or 7. Samples (1ml) of receptor solution were taken 
periodically, replaced with fresh pre-heated buffer and analysed with reverse-phase high 
performance liquid chromatography (Hypersil ODS, 5 µm particle size, 250 x 4 mm) using 
UV detection at 248 nm. The high performance liquid chromatography (HPLC) system 
consisted of a Spectra-Physics SP800 ternary HPLC pump, a Spectroflow 757 UV detector 
and an HP 3395 integrator. A mobile phase of 60:40 v/v methanol/water was used at 1.1 
ml/min which gave a retention time (Rt) of 5.2 min. The calibration curve was linear over 0-
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25 µg/ml (R
2
> 0.99) with a limit of detection (LoD) and quantification (LoQ) of 0.87 µg/ml 
and 2.89 µg/ml respectively. The injection volume was set at 20 µl. 
2.6 Stability testing 
Stability testing of the 1% w/w hydrocortisone gel formulations (Carbopol- and Metolose-
based) was carried out over twelve weeks at room temperature. Gel samples were diluted 
with water, centrifuged then filtered before the filtrate was analysed by reverse-phase HPLC 
to determine drug leakage from the particles into the gel, whereas the collected microparticles 
were dissolved in ethanol and analysed by UV to establish the percentage of encapsulated 
drug remaining. 
2.7 Statistical analysis 
Data are expressed as mean ± standard deviation (SD). Statistical significance was assessed 
using the Student’s t-test, for two batch drug release comparison, and one way analysis of 
variance (ANOVA), when the difference between the results of more than two 
microparticulate systems are evaluated (Genstat; version 12). The correlation coefficient (R
2
) 
is reported in these cases. For permeation experiments, statistical analysis was carried out 
using the Mann-Whitney U test. In all cases, p < 0.05 denotes significance.  
3 Results  
The characteristics of our pH-responsive microparticles were described in our previous 
articles (10, 11). Briefly, the encapsulation efficiency of the drug was relatively high with 
over 70% of the drug encapsulated in all cases (10, 11). Differential scanning calorimetry and 
X-ray powder diffraction data showed that hydrocortisone was encapsulated as a solid 
solution, except for the oil-in-oil microparticles produced at 25% w/w drug-loading where 
about 50% of the drug was incorporated in its crystalline form (10). Scanning electron 
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microscopy confirmed these results with visible drug crystals only observed at the surface of 
25% w/w drug-loaded oil-in-oil microparticles and not in images of particles with lower drug 
contents.  
Hydrocortisone release profiles from the microparticles at different pH values are presented 
in Figure 1. Eudragit L100 microparticles prepared from the oil-in-oil emulsification method 
showed better pH-controlled release than the spray dried microparticles, with negligible 
hydrocortisone release at pH 5 at 2.5% and 10% w/w drug-loading (Figure 1, A and B) and in 
agreement with results obtained from dissolution testing (10). In contrast, significant drug 
release was observed at both pH 5.0 and 5.5 for 2.5% w/w drug-loaded Eudragit L100 
microparticles produced from the spray drying method (Figure 1, D). In both cases, the drug 
was incorporated at a level well below its solubility within the polymer matrix (11) 
suggesting that differences in drug release profiles are related to the method of 
microencapsulation rather than the level of drug loading. In fact, solvent evaporation during 
the spray drying process occurs rapidly (due to the high temperatures used) leading to the 
formation of porous microparticles. The porosity of these microparticles might be in part 
implicated in the burst release effect observed at low pH values (5.0 and 5.5), where the 
polymers are not soluble. Another explanation for this phenomenon is the possible deposition 
of the drug on or near the surface of the microparticles leading to non-pH-controlled drug 
leakage.  Loading the microparticles with 25% hydrocortisone exceeds the solubility of the 
drug in the polymer and results in uncontrolled burst release of the excess drug from both the 
spray dried and oil-in-oil generated materials (Figures 1C and F) 
INSERT FIGURE 1 
 
Despite differences in drug release profiles, further analysis of hydrocortisone release from 
the 2.5% w/w drug-containing Eudragit L100 microparticles at different time points (Table 1) 
showed no statistical difference in terms of pH-responsiveness (p>0.05). The pH-
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responsiveness of Eudragit L100 is reported in Table 1 as percentage hydrocortisone release 
per pH unit. These values were obtained by plotting the percentage drug release against pH 
and calculated from the gradient of the line of best fit. These data confirm that the preparation 
method did not alter the pH-responsiveness of the polymer and is supported by DSC, X-ray 
and Raman analysis reported in our previous study (10) as no differences were observed 
between unprocessed polymer and the microparticles obtained from the different preparation 
methods at the various drug loadings.  
INSERT TABLE 1 
 
Maximum release rates (Jmax) for the different microparticles batches are reported in Table 2 
At pH 5, maximum drug release rates were significantly higher for the spray dried 
microparticles than the oil-in-oil produced material (p<0.05). At pH7, where the polymer 
dissolves, the maximum release rate and time to achieve this were not significantly different 
(P>0.05) between the two production methods.  These findings support the view that apart 
from the burst release effect observed with the spray dried microparticles (about 30% after 3 
hrs, Figure 1, D), which is responsible for the relatively high flux values at pH 5, the two 
preparation methods produce equally pH-responsive particles.  
INSERT TABLE 2 
Release testing showed that incorporating 10% w/w hydrocortisone-loaded microparticles 
into the Carbopol- and HPMC-based gel formulations maintained pH-responsiveness (Figure 
2, A and C), similar to that observed for the microparticles alone (Figure 1, B). However, 
drug release from the neutralised Carbopol gel showed significantly lower drug release at pH 
7 (Figure 2, B), which is probably due to increased viscosity of the formulation. Because the 
pKa of Carbopol is 6.0±0.5, the carboxylate moiety on the polymer backbone ionizes with 
increased pH, resulting in repulsion between the negative charges, which adds to the swelling 
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of the polymer thus increases viscosity (15). This also demonstrates that adjusting 
formulation viscosity can confer further slow-release properties to the pH-responsive 
formulation.  
INSERT FIGURE 2 
Permeation across full thickness porcine skin was measured using receptor compartments 
containing phosphate buffer at pH 5 or 7. The skin was equilibrated with the buffer for 2 hrs 
prior to the experiment to develop the appropriate surface pH. A comparison of the 
cumulative amount of hydrocortisone permeating the skin after 24 hours is given in Figure 3. 
Permeation from Carbopol hydrogels before and after neutralisation showed similar pH-
responsiveness to the free powder, with about 4-fold greater permeation of the drug after 24 
hours at pH 7 compared to pH 5 (p<0.05). Similarly, the HPMC-based gel formulation 
showed significantly higher drug permeation at pH 7 (about 5-fold greater than the amount 
permeated after 24 hours at pH 5). In contrast to drug permeation from the particles, the 
difference in hydrocortisone permeation from a saturated aqueous solution at pH 5 and 7 is 
statistically non-significant. This is expected as the solubility of the drug at pH 5 and 7 was 
found to be essentially the same (0.252±0.01 mg/ml) (11).  
INSERT FIGURE 3 
Increasing the pH of the Carbopol formulation to pH 5, in order to prevent skin pH alteration, 
did not affect the amount of drug permeating the skin at pH 5 and 7 (Figure 3).  Nonetheless, 
increasing the pH of the formulation from 3 to 5 could potentially negatively influence the 
efficient encapsulation of the drug within Eudragit L100 microparticles. Eudragit L100 has a 
reported pKa value of 6.45±0.03, this means that a greater degree of carboxyl group 
ionisation will be present at pH 5 compared to pH 3. Increased polymer ionisation might lead 
to greater swelling and potentially a greater degree of drug loss into the external hydrogel 
phase through diffusion; drug leakage from the incorporated microparticles can result in the 
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loss of formulation pH-responsive properties. In this study, the possible effects of Carbopol 
hydrogel neutralisation on formulation stability was monitored before and after the addition 
of the base (Figure 4, A), and compared to drug leakage from microparticles in the HPMC gel 
(Figure 4, B). 
INSERT FIGURE 4 
4 Discussion 
In recent years, polymeric nano- and micro-particulate systems have emerged as promising 
systems for site-specific drug delivery and they have been extensively studied for oral, 
parenteral and pulmonary drug administration (e.g. 12, 16).  The application of such 
polymeric systems in topical drug delivery is thought to offer a number of advantages, 
including control of drug release and protection of unstable compounds (17).  
Microencapsulation, using polymers such as poly(lactide-co-glycolide acid) (PLGA), for 
controlled-release topical drug delivery has previously been reported, for example to prolong 
the residence time of sunscreen agents in the stratum corneum (18) or to target vitamin A to 
the upper layers of the skin (19). However, reports concerning percutaneous uptake of nano- 
and micro-particles are contradictory (20, 21), though deposition into the follicles is well 
documented (22, 23).  
Unlike previous studies where polymeric particulate systems have been designed to cross the 
intact skin layer or to accumulate in follicular openings, this study relies on a targeted drug 
delivery approach whereby microparticle dissolution occurs on the surface of the skin 
according to pH and results in drug release at the diseased site. Thus, the discrepancy in skin 
surface pH observed in normal and diseased skin is used to trigger drug release at the target 
site and so minimises delivery to non-diseased sites.  
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4.1 Hydrocortisone release from Eudragit L100 microparticles 
The usefulness of drug release data in formulation design has been discussed by Flynn and 
Poulsen (24, 25). Because the efficiency of creams, ointments and gel products is dependent 
on drug release, in-vitro release testing constitutes an important and valuable tool for quality 
control. This is particularly important for controlled release drug formulations. In fact, the use 
of the diffusion model for polyvinyl alcohol (PVA) microparticles was shown to better 
differentiate between samples in terms of controlled-drug release kinetics compared to other 
methods of release testing such as dissolution studies (26).  
The data in Figure 1 and Tables 1 and 2 clearly illustrate pH control over drug release from 
the Eudragit microparticles.  Comparing Figures 1A and 1D, the spray dried materials give 
significantly greater drug release at pH 5 than from the oil-in-oil particles.  However, with 
increasing pH, release from particles produced by either process were similarly pH 
responsive (Table 1) which indicates that the initial non-pH controlled release from the spray 
dried materials is due to poor drug encapsulation, perhaps from surface enrichment or the 
production of porous materials in which the polymer does not control release.  Well-
controlled drug release from oil-in-oil manufactured particles was achieved; for example, at a 
drug loading of 10%, only 1.02 µg cm
-2
 hr
-1
 hydrocortisone was released at pH 5 whereas the 
same particles liberated 26.6 µg cm
-2
 hr
-1
 at pH 7.         
4.2 Formulation development 
There are numerous examples on the market for powdered topical formulations such as, talc, 
zinc oxide and kaolin (27). However, such formulations are applied as drying, protective or 
lubricant agents. Difficulties associated with the application and dosing of powders can be 
overcome by incorporating them into a vehicle such as a cream, ointment, lotion or a gel.  
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The main criteria for incorporating powders intended for topical drug delivery into 
conventional formulations is that the individual powder particles should be impalpable, i.e. 
incapable of being perceived as individual particles by our sense of touch (28). In general, 
particles less than 50 µm in their longest dimension are invisible to the senses (17). A coarser 
powder can make the preparation gritty and cosmetically unacceptable. Microparticles 
prepared from the oil-in-oil emulsification process at 2.5% and 10% w/w drug-content fulfil 
this criterion with a mean equivalent circular area particle diameter of 41.5±0.6 and 
39.3±11.2 µm respectively. The mean size of these microparticles can be further reduced 
using a higher homogenisation speed during the manufacturing process.  
In this study, 10% w/w hydrocortisone-loaded Eudragit L100 microparticles were 
incorporated into a gel formulation to obtain a final drug content of 1% w/w, which is within 
the 0.5 to 2.5% w/w topical concentration commonly used for hydrocortisone. The use of 
microparticles with a lower drug-loading, e.g. 2.5% w/w, will require the incorporation of a 
larger amount of powder into the gel formulation, which would result in a preparation with a 
paste-like consistency that is difficult to spread (29).  
For formulation development, two commonly used gelling materials were investigated; 
Carbopol 940 and Metolose 90SH-SR (HPMC). The carbomer (Carbopol 940) used in this 
study is an acrylic acid polymer cross-linked with allyl ethers of pentaerythritol (30, 31). The 
individual Carbopol cross-linked polymer particles swell when dispersed in an aqueous 
solution forming a colloidal, mucilage-like dispersion. Dermatological applications of 
Carbopol polymers are numerous; examples include formulations of local anaesthetics and 
cosmetics (e.g. 32-34). Carbopol polymers are also reported to have good suspending 
properties (35). For example, a permanent sand (average particle size of 0.06 cm) suspension 
was achieved using as little as 0.25% Carbopol 934 (36). The same physical stability was 
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reported for other insoluble compounds such as, pentobarbital sodium, chloramphenicol and 
sulphadimidine (34, 37). 
Metolose 90SH-SR, a high-viscosity grade of hydroxypropyl methyl cellulose (HPMC), was 
also used. This is an example of a fully soluble polymer, which dissolves in aqueous media to 
form a highly viscous gel due to its relatively high molecular weight. The use of HPMC for 
dermatological gels has also been reported in the literature (34, 38). However, unlike 
Carbopol, this is a neutral polymer. In fact, the pH of the two prepared gels using 1.5% w/w 
Carbopol 940 or 2% w/w Metolose 90SH-SR were found to be 3.23±0.01 and 7.40±0.09 
respectively. The addition of Eudragit L100 microparticles did not change the pH of the 
Carbopol gel, but for the HPMC-containing gel the pH was reduced to about 5.2 due to the 
anionic nature of Eudragit L100.  
Carbopol 940 is also an anionic polymer whose use in a topical drug formulation can also 
modulate skin surface pH. This effect can be detrimental for the controlled pH-responsive 
release of hydrocortisone from the microparticles, as a reduced pH can result in reduced or no 
drug release at the affected areas of the skin. To circumvent this problem, the Carbopol 
hydrogel formulation was neutralised to pH 5.0 using 0.5 M NaOH. The use of other bases 
for Carbopol neutralisation, such as monoethaloamine and triethylamine, has been reported in 
the literature (28, 32, 33). However, these stronger bases are usually used for gel formulations 
prepared from a hydro-alcoholic co-solvent system, as the inclusion of an alcohol can affect 
polymer solubility leading to the precipitation of the neutralised Carbopol salt (39). It is 
therefore essential to select the appropriate neutraliser depending on the alcohol content of 
the formulation. Since, in this study an aqueous Carbopol formulation was employed, sodium 
hydroxide was selected to neutralise the polymer.  
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4.3 Release and permeation testing of microparticle-containing 
formulations 
The results in Figure 2 illustrate that pH responsive release of hydrocortisone from the oil-in-
oil generated particles was maintained when incorporated into formulations gelled with 
Carbopol or HPMC, though neutralizing the Carbopol gel did negatively impact on drug 
release.  As described above, release from topical preparations provides a good indication as 
to permeation across skin membranes and the release data did indeed mirror the percutaneous 
absorption values in Figure 3.  Thus the particles alone or in gelled formulations all delivered 
significantly greater amounts of hydrocortisone through porcine skin at pH 7 than at pH 5, in 
contrast to a standard saturated aqueous solution from which drug permeation was the same 
at both pH values.  It is notable that the 10% particles showed a 26-fold increase in drug 
release at pH 7 compared to pH 5 (Table 2) but only a 4-fold increase in permeation at the 
higher pH value.  This discrepancy reflects the presence of the stratum corneum as the rate 
limiting barrier to permeation of the liberated drug whereas the release studies provide no 
such barrier.   
Our approach demonstrates that it is feasible to deliver the active ingredient to diseased skin 
sites with minimal delivery to surrounding (non-involved) tissue.  Current formulations, such 
as typical creams, contain various ingredients which can act as permeation enhancers, 
including surfactants and fragrance agents such as terpenes.  Such enhancers could promote 
the formation of a drug depot within the non-involved skin and hence increase potential 
adverse effects.  Whilst we have not explored the potential for depot formation on long term 
use at diseased skin sites, our in-vitro proof-of-principle studies demonstrate that an in-vivo 
evaluation of our pH-triggered and targeted drug delivery formulation is merited.     
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4.4 Stability testing 
The Eudragit L100 microparticles were predominantly stable within the Carbopol hydrogel 
with about 5% drug leakage into the bulk of the formulation before neutralisation (Figure 4). 
This is probably due to the high glass transition temperature of Eudragit L100 (150
0
 C, (40)) 
which limits drug movement and diffusion into the external environment. In fact, the 
prevention of drug molecule aggregation, which can lead to crystal growth, through 
encapsulation into polymers with high transition temperatures, has been extensively studied 
(17, 41, 42). The limited diffusion of hydrocortisone from the Eudragit L100 microparticles 
coupled with the poor solubility of the drug in aqueous media explains the minimal drug 
leakage from the microparticles.  
After Carbopol hydrogel neutralisation at week 6, drug leakage from the microparticles 
increased to about 15%. This is probably due to increased Eudragit L100 ionisation and 
swelling as discussed earlier. However, this value remained constant over the next 6 weeks, 
with 85% of the drug originally encapsulated remaining within the microparticles. With the 
HPMC-based gel formulation, hydrocortisone leakage from Eudragit L100 microparticles 
was minimal over the 12 weeks testing period, as demonstrated in Figure 4, B. A longer-term 
stability study is nonetheless necessary to fully evaluate the commercial viability of these 
novel pH-responsive formulations.  
5 Conclusion 
Eudragit L100 microparticles loaded with hydrocortisone intended for targeted delivery to 
atopic dermatitis areas of the skin were produced by two different methods, oil-in-oil 
microencapsulation and spray drying.  Release from both batches of microparticles was 
equally pH-dependent though the particles produced by spray drying also gave significant 
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non-polymer controlled burst release, probably due to their porous nature or as a result of 
drug enrichment on the surface of these particles.  
The release studies showed that the oil-in-oil generated particles deliver essentially no drug at 
normal (intact) skin pH (5.0 – 5.5) but that delivery can be targeted and controlled to atopic 
dermatitis skin where the pH is elevated to around pH 6.0-6.5. This pH-responsive release 
was maintained upon the incorporation of these microparticles into Carbopol- and HPMC-
based gel formulations. In-vitro hydrocortisone permeation studies from these novel pH-
responsive formulations showed a 4 to 5-fold increase in drug permeation after 24 hours at 
pH 7 compared to pH 5. A 12-week preliminary stability study monitored drug leakage from 
the incorporated microparticles which would result in a loss of pH-responsiveness. The study 
demonstrated relatively good stability of both formulations with better stability of the 
microparticles incorporated in the HPMC gel. Nonetheless, a long-term stability study and a 
blanching assay are necessary to fully evaluate the commercial viability and clinical efficacy 
of such formulations. 
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Legend to Figures 
 
Figure 1. Hydrocortisone release profiles from: A, B and C) 2.5%, 10% and 25% w/w 
hydrocortisone-containing microparticles produced from the oil/oil method and D, E and F) 
2.5%, 10% and 25% w/w drug-loaded microparticles obtained from the spray drying 
technique (mean ± SD, n=3). 
 
Figure 2. Release of hydrocortisone from: A) Carbopol hydrogel, B) neutralised Carbopol 
hydrogel and C) HPMC gel. Results are presented as mean ± SD, n=3-5. 
 
Figure 3. Cumulative hydrocortisone (HC) permeation at pH 5 and 7 after 24 hrs from a 
saturated solution of hydrocortisone, 10% w/w hydrocortisone-loaded Eudragit L100 
microparticles and various microparticle-containing gel formulations. Data are shown as 
mean ± SD, n=5. 
 
Figure 4. Stability testing of 10% w/w hydrocortisone-loaded Eudragit L100 microparticles 
incorporated into; Top) Carbopol hydrogel and Bottom) HPMC gel. The percentage of drug 
leaking into the bulk of the formulation and that remaining within the microparticles was 
determined before and after Carbopol neutralisation at 6 weeks.  Data is presented as mean ± 
SD, n= 3. 
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Figure 2 
 
  
 
 
  
 
0
20
40
60
80
100
0 1 2 3 4 5
%
 R
e
le
as
e
Time (hrs)
0
20
40
60
80
100
0 1 2 3 4 5
%
 R
e
le
as
e
Time (hrs)
0
20
40
60
80
100
0 1 2 3 4 5
%
 R
e
le
as
e
Time (hrs)
pH 7
pH 5
A) B) 
C) 
26 
 
Figure 3. 
 
 
 
  
0
10
20
30
40
50
60
70
80
90
Sa
tu
ra
te
d
 H
C
 
so
lu
ti
o
n
 
M
ic
ro
p
ar
ti
cl
es
C
ar
b
o
p
o
l g
el
N
eu
tr
al
is
ed
 
C
ar
b
o
p
o
l g
el
H
P
M
C
 g
el
C
u
m
u
la
ti
ve
 H
C
 a
t 
2
4
 h
rs
 (
µ
g/
cm
2
)
Tested formulation
pH 7
pH 5
27 
 
Figure 4. 
 
 
 
 
 
 
  
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
%
 h
yd
ro
co
rt
is
o
n
e
Time (weeks)
% remaining
% leakage
pH increased to 5 at week 6
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14
%
 h
yd
ro
o
cr
ti
so
n
e
Time (weeks)
% remaining
% leakage
28 
 
 
Table 1. pH-responsiveness of 2.5% w/w hydrocortisone-loaded Eudragit L100 
microparticles reported as percentage hydrocortisone released per unit pH, calculated at 3, 4 
and 5 hours.  
 
Time Spray drying Oil/oil method 
3 hours 31.2±3.66 37.2±8.62 
4 hours 33.7±3.14 44.3±6.69 
5 hours 31.9±4.19 48.8±5.33 
 
 
  
29 
 
 
 
Table 2. Maximum release rates (Jmax) (µg cm
-2
 hr
-1
) and time to maximum release rates 
(Tmax) calculated from the release profile of hydrocortisone for the different microparticles 
prepared from the spray drying and oil-in-oil emulsification methods. 
Method Drug 
loading 
(% w/w) 
pH 5 pH 7 
Jmax Tmax Jmax Tmax 
Spray drying 2.5% 7.23±2.11 1.5 hr 17.3±2.94 1.5 hr 
10% 18.5±1.81 1.5 hr 24.6±4.48 45 min 
25% 12.6±0.71 45 min 16.6±5.98 45 min 
Oil/oil 
method 
2.5% 1.26±0.16 1.5 hr 19.6±3.54 1.5 hr 
10% 1.02±0.24 1.5 hr 26.6±4.50 1.5 hr 
25% 5.20±2.26 1.5 hr 18.8±1.30 1.5 hr 
 
 
 
 
